Development of new strategies of human antitumor dendritic cell vaccines

Informazioni relative al progetto

MYRTO-GEORDIA TRAKAT

ID dell’accordo di sovvenzione: QLK2-CT-1999-51390

Progetto chiuso

Data di avvio 1 Agosto 2000

Data di completamento 31 Luglio 2002

Finanziato da

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Costo totale € 159 400,00

Contributo UE € 159 400,00

Coordinato da

UNIVERSITE LIBRE DE BRUXELLES
Belgium

Obiettivo

The project aims to investigate in healthy donors and in melanoma patients, strategies that could improve the generation of MAGE-specific antitumor cytotoxic immune responses by vaccination with autologous dendritic cells.

Campo scientifico

• medical and health sciences › clinical medicine › oncology › skin cancer › melanoma
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programma(i)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Argomento(i)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

RGI - Research grants (individual fellowships)

Coordinatore

UNIVERSITE LIBRE DE BRUXELLES

• Contributo UE: Nessun dato
• Indirizzo: Route de Lennik 808 ; 1070 BRUXELLES ; Belgio
• Costo totale: Nessun dato